Form 8-K

8-K — Nuvectis Pharma, Inc.

Accession: 0001104659-26-076624

Filed: 2026-06-23

Period: 2026-06-22

CIK: 0001875558

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2618439d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618439d1_ex99-1.htm)

GRAPHIC (tm2618439d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618439d1_8k.htm · Sequence: 1

false

0001875558

2026-06-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

June 22, 2026

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction

of Incorporation)

001-41264

(Commission File Number)

86-2405608

(IRS Employer Identification No.)

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

(201) 614-3150

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the

Exchange Act:

Title of Class

Trading Symbol(s)

Exchange Name

Common Stock

NVCT

Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01.

Entry into a Material Definitive Agreement.

Haisco License Agreement

On June 22, 2026, Nuvectis

Pharma, Inc., a Delaware corporation (the “Company”), entered into a license agreement (the “License Agreement”)

with Haisco Pharmaceutical Group Co., Ltd. (“Haisco”). Pursuant to the License Agreement, Haisco will grant the Company an

exclusive, royalty-bearing license for the development, manufacturing, and commercialization rights of HSK39297 (“NXP100”),

a Complement Factor B inhibitor in late-stage development for the treatment of complement-mediated diseases, and HSK42360 (“NXP200”),

a BRAF inhibitor for the treatment of BRAF-mutated malignancies.

Under the terms of the License

Agreement, the Company will be responsible for the development, manufacturing, and commercialization of NXP100 and NXP200 in the Territory,

which includes all countries except for The People’s Republic of China, Hong Kong, Macau, Taiwan, India, Brunei, Cambodia, Indonesia,

Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam with respect to NXP100, and all countries except for The People’s

Republic of China, Hong Kong, Macau and Taiwan with respect to NXP200 (the “Territory”). Haisco will be entitled to a percentage

of sublicensing revenue generated in the Territory and will continue to be responsible for current ongoing development activities in China.

Under the terms of and as consideration for entering into the License Agreement, the Company will pay to Haisco an upfront payment of

$20 million, and certain initial development milestone payments of up to $20 million may become payable upon achievement of specified

early clinical development events. Haisco will also be eligible to receive up to an additional $1.4 billion as contingent payments based

on future development, regulatory and commercial milestones being met, as well as tiered royalties in the high-single digits to mid-teens

based upon net sales of NXP100 and NXP200 in the Territory, subject to reduction under certain circumstances as provided in the License

Agreement. The Company is required to pay Haisco a low double digit percentage of the fair market value of the licensed rights if the

Company undergoes a change of control within eighteen months of the execution of the License Agreement.

The Company may not exploit

any compound or product, other than a licensed product, whose primary mechanism of action is to bind to or functionally inhibit the BRAF

kinase or the Factor B, with a customary acquirer exception.

The License Agreement will

become effective subject to certain financing conditions, which the Company is required to meet to ensure sufficient capital for the development

of the licensed products. The License Agreement will continue in full force and effect until, on a Licensed Product-by-Licensed Product

(as defined in the License Agreement) basis, the expiration of the Company’s payment obligations thereunder with respect to such

Licensed Product. The License Agreement contains customary provisions relating to confidentiality, representations and warranties, and

indemnification.

The foregoing summary of the

License Agreement is not complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which

the Company expects to file with the U.S. Securities and Exchange Commission as an exhibit to its Quarterly Report on Form 10-Q for the

quarter ending June 30, 2026.

Item 8.01.

Other Events.

On June 22, 2026, the Company

issued a press release to announce its entry into the License Agreement. The full text of the press release is filed as Exhibit

99.1 to this Current Report on Form 8-K and is incorporated herein by reference (except for the third and fourth paragraphs of the press

release).

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed herewith:

Exhibit

Number

Description

99.1

Press release issued by Nuvectis Pharma, Inc., dated June 22, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

Nuvectis Pharma, Inc.

(Registrant)

Date: June 23, 2026

By:

/s/ Ron Bentsur

Ron Bentsur

Chairman, Chief Executive Officer and President

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618439d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Nuvectis Announces

Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In

Class Clinical-Stage Compounds

· The

transaction transforms Nuvectis into a late-stage clinical development company by expanding

its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor

B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing

of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies.

· NXP100

(HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated

diseases. Current development status in China includes:

o  Two

Marketing Authorization Applications (MAAs) are under review for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH); The applications

seek approvals for NXP100 for the treatment of PNH in treatment-naive patients and in patients who failed treatment with a Complement

protein 5 (C5) inhibitor.

Successful completion of a Phase 2 and ongoing Phase 3 trial in Immunoglobulin A Nephropathy (IgAN).

Ongoing Phase 2 trial in Lupus Nephritis (LN).

· NXP200

(HSK42360): An oral, brain penetrant, paradox-breaker BRAF inhibitor for the treatment of

BRAF V600X-mutated and Class II/III non-V600-mutated malignancies. NXP200 has generated single

agent durable responses in several tumor types including CNS, colorectal, melanoma, non-small-cell

lung cancer, papillary thyroid and others. Paradox breaking represents a next generation

approach to targeting BRAF. A Phase 1b study in China is ongoing.

· Strong

intellectual property protection for both compounds.

· Nuvectis

will hold a conference call today at 8:30 AM ET to introduce its newly in-licensed products.

Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE)

- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company

focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced a

strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco Pharmaceutical Group (“Haisco”)

to two potentially best in-class clinical-stage compounds. Nuvectis will hold a conference call today at 8:30 AM ET to introduce its

newly in-licensed products.

Haisco (SHE ticker code: 002653) is

a leading fully-integrated pharmaceutical company with approximately 50 marketed products and 70 research programs, most recently recognized

for successfully executing licensing deals with Eli Lilly and AbbVie (both in 2Q2026), and the phase 3 success of envudeucitinib in plaque

psoriasis (1Q2026), a compound which Haisco discovered and advanced through development until it was licensed to Alumis, Inc.

Ron Bentsur, Chairman and Chief Executive

Officer of Nuvectis, commented, “The in-licensing of the two clinical stage drug candidates with best-in-class potential represents

an expansion of Nuvectis’ pipeline and strategy.” Mr. Bentsur continued, “NXP100 is a late-stage Factor B inhibitor

with the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily

oral treatment option for these diseases requiring life-long treatment. With regards to NXP200, the paradox-breaker BRAF inhibitor, the

ability to overcome the limitations of older generation BRAF inhibitors, a validated pharmaceutical class, is an area of great interest

and we are very pleased to add NXP200 to our oncology pipeline, in which NXP900, our incumbent drug candidate, is progressing toward

important clinical inflection points from the ongoing Phase 1b starting in this summer.” Mr. Bentsur concluded, “With tremendous

in-house drug development capabilities and two recently completed licensing deals with Eli Lilly and AbbVie, Haisco is recognized as

a premier drug development company with global reach. We are thankful for this opportunity and are privileged to partner with Haisco

as we look forward to our collaboration and advancing these development programs.”

Dr. Pangke Yan, Chief Executive Officer

of Haisco, commented, “This licensing deal, in addition to our recently completed deals, further strengthens Haisco’s global

research and development presence and we are excited to collaborate with Nuvectis on these two projects. We believe that Nuvectis has

the relevant experience and capabilities required to advance these projects and that together we can accelerate and offer high-quality

treatment options to patients worldwide.”

Clinical / Regulatory Status in

China and Key Data Summaries for NXP100 and NXP200

NXP100 (HSK39297)

Paroxysmal Nocturnal Hemoglobinuria

(PNH)

Two MAAs for NXP100 have been submitted

to the Chinese National Medical Products Administration (NMPA) and are currently under review:

The first MAA is based on positive data

from a completed randomized, open-label, active comparator-controlled, Phase 3 study (clinicaltrials.gov NCT06799546). In this study,

73 adult Chinese treatment naïve PNH patients were randomized 1:1 to receive either NXP100 or Soliris® (eculizumab),

a Complement C5 inhibitor, for a 24-week treatment period. The primary efficacy endpoint was to evaluate the proportion of patients achieving

hemoglobin (Hgb) levels ≥ 12 g/dL on at least three out of four measurements between Week 18 and Week 24 in the absence of red blood

cell (RBC) transfusions. Treatment with NXP100 was superior to treatment with eculizumab in the primary and all key secondary endpoints

(overall increase in Hgb levels, reducing the requirement for RBC transfusions, and avoiding extravascular hemolysis).

Parameter

NXP100

(n=37)

Eculizumab

(N=36)

Primary

Endpoint

Proportion of participants

achieving Hgb levels ≥12 g/dL without RBC transfusion % (95% CI)

59.5 (43.2, 75.7)

8.3 (2.8, 19.4)

p-Value

0.001

The second MAA is based on positive

data from a completed single-arm, Phase 3 study (clinicaltrials.gov NCT07052838). In this study, 36 adult Chinese patients with PNH and

persistent anemia who failed treatment with C5 inhibitors were treated with NXP100 for a 24-week treatment period. The primary efficacy

endpoint was to evaluate the proportion of patients achieving Hgb levels ≥ 12 g/dL on at least three out of four measurements

between Week 18 and Week 24 in the absence of RBC transfusions from Week 2, with efficacy prospectively defined as having the lower bound

of the 95% CI for the response rate exceeding 20%. The study met the primary and all key secondary endpoints (overall increase in Hgb

levels, reducing the requirement for RBC transfusions, and avoiding extravascular hemolysis).

Parameter

NXP100

(n=36)

Primary

Endpoint

Proportion

of participants achieving Hgb levels ≥12 g/dL without RBC transfusion % (95% CI)

52.8

(35.5, 69.6)

Immunoglobulin A Nephropathy (IgAN)

In China, a Phase 3 clinical trial (NCT07390123)

is ongoing in IgAN following positive data from a randomized, placebo-controlled Phase 2 (NCT06670352). In the Phase 2 study, the efficacy

of treatment with NXP100 was investigated in a 24-week treatment period versus placebo with efficacy defined as reduction in the ratio

of 24-hour urine protein to creatinine (24h-UPCR) compared to baseline after 12 weeks of treatment. Treatment with NXP100 resulted in

clinically meaningful reduction in 24h-UPCR after 4 weeks, and the magnitude of the treatment effect increased over time. NXP100 also

demonstrated excellent estimated Glomerular Filtration Rate (eGFR) control (a secondary endpoint) vs placebo in the study.

Parameter

Week

(Primary Endpoint)

Week

Reduction in 24h-UPCR relative to

baseline vs. placebo

NXP100 N=24

Placebo N=21

-33%

-45.3%

-57.7%

In addition, a Phase 2 of NXP100 for

the treatment of LN is also ongoing in China.

NXP100 Competitive Landscape

and Market Analysis

· The

PNH market size is expected to be >$5.0BN in 2026 with the injectable C5 inhibitor drugs

Soliris® and Ultomiris®, marketed by Alexion/AstraZeneca Rare

Disease, projected to be approximately $4.5BN of the total market. The PNH market is expected

to more than double to >$10BN within 8 years. Soliris and Ultomiris were the centerpiece

of Astra Zeneca’s acquisition of Alexion in 2021 for $39BN.

· Fabhalta

(iptacopan, launched in 2024), marketed by Novartis, is the only FDA approved Complement

Factor B inhibitor with approvals in PNH, IgAN and C3G.

o Fabhalta®is

administered orally, twice per day, vs NXP100 which is administered once a day.

o Fabhalta®

is currently also being investigated in several clinical trials, including LN, Myasthenia

Gravis (MG) and dry Age-related Macular Degeneration (dAMD).

o Fabhalta®

peak annual revenue in the currently approved indications is projected by analysts to reach

$5B to $10B. The PNH and IgAN markets are estimated to reach >$20BN combined within the

next 10 years.

· In

randomized Phase 3 clinical trials in patients with PNH, treatment with either NXP100 or

Fabhalta® was superior to treatment with C5 inhibitors, with comparable treatment

effect for NXP100 and Fabhalta across studies, positioning CFBis to potentially dominate

the PNH market over time.

· In

IgAN, the Phase 2 data suggests that NXP100 has the potential to be comparable to the best

injectable APRIL/BAFF inhibitors on the key renal function endpoints, including 24-hour UPCR

and eGFR control.

· In

cross study comparisons, the observed safety profile of NXP100 appears to be similar to that

of Fabhalta®.

NXP200 (HSK42360)

Overview, Competitive Landscape

and Market Analysis

BRAF is a validated therapeutic target

in oncology with first generation drugs such as Tafinlar® (dabrafenib, marketed by Novartis) and Braftovi®

(encorafenib, marketed by Pfizer) approved in multiple indications. These first-generation BRAF inhibitors effectively inhibit the V600-mutated

BRAF, which results in initial antitumor activity, but also leads to paradoxical activation through stimulation of the MAPK signaling

pathway, causing treatment resistance and development of secondary malignancies, primarily skin squamous cancer and other skin-related

side effects. The current solution to the paradoxical activation problem is concomitant administration of MEK inhibitors, but while the

skin side effects are reduced, they are not eliminated and acquired resistance still emerges. In addition, Class II and III BRAF mutations

are not inhibited by first generation BRAF inhibitors. Designed to overcome this paradoxical activation, paradox-breaking BRAF inhibitors

represent the next generation approach to targeting BRAF. There are currently several paradox breakers BRAF inhibitors in clinical development,

none are FDA approved.

Available data to date suggests that

NXP200 is the only paradox-breaker BRAF inhibitor that has consistently demonstrated single agent activity in CNS tumors but, importantly,

also in additional solid tumor types that harbor BRAF mutations. In a completed dose escalation study of NXP200 as monotherapy in heavily

pre-treated patients with BRAF V600-mutated solid tumors, including ones previously treated with BRAF/MEK inhibitors, NXP200 demonstrated

an acceptable safety profile and single-agent durable clinical activity in various tumor types, including a >40% response rate in

low- and high-grade adult glioma, including one Complete Response. Durable responses were also demonstrated in non-small cell lung cancer

(NSCLC), colorectal and papillary thyroid cancers.

In this dose escalation program, treatment

with a first-generation, free base form of NXP200 was used. A second-generation salt form of NXP200 was recently developed to enhance

the pharmacokinetic (PK) profile of NXP200, and early data indeed demonstrate a marked improved PK and greater single agent clinical

activity. Thus, with favorable pharmacology, promising early clinical data and possible applicability across V600, Class I and Class

II-altered solid tumors, NXP200 could emerge as a best-in-class next-generation BRAF inhibitor. NXP200 is currently in a Phase 1b study

in China.

The combined annual revenue for the

first-generation BRAF inhibitors, typically administered in combination with a MEK inhibitor to overcome paradoxical activation, is estimated

at approximately $4BN.

Of note, in April 2026, Servier acquired

Day One Biopharmaceuticals for $2.5BN with its only FDA approved drug, Ojemda (tovorafenib), a first generation BRAF inhibitor which

is indicated for the treatment of relapsed or refractory pediatric in BRAF-altered low-grade glioma. With projected 2026 sales of $225-250M,

sales of Ojemda represent only 6% of the current BRAF market.

Intellectual Property

Both compounds have strong intellectual

property protection including composition of matter patents for NXP100 and NXP200 which expire in 2043 and 2042, respectively.

Transaction Terms

Nuvectis in-licensed exclusive worldwide

Ex-China rights for two drug candidates from Haisco. Haisco also retains rights for NXP100 in India and certain Southeast Asia territories.

Haisco will receive upfront and near-term payments totaling up to USD $40 million and is eligible to receive up to USD $1.421BN in additional

development, regulatory, and commercial milestone payments, as well as tiered royalties on future net sales. The agreement is subject

to certain financing conditions which Nuvectis is required to meet to ensure sufficient capital for the development of the licensed products.

Conference Call and Webcast Information

Date: Monday, June 22, 2026, at 8:30 AM ET

Participant Dial-in (U.S.): 1-877-407-0752 or 1-201-389-0912

Webcast Access: Click Here

A replay of the webcast will be available

on the Investors section of the Nuvectis website at: https://nuvectis.com/investors/

Third-party products mentioned herein

are the trademarks of their respective owners.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical

stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions

and oncology. The Company’s pipeline includes NXP100, a complement Factor B inhibitor in development for the treatment of complement-mediated

diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.

NXP100 is a late-stage Factor B inhibitor

with best-in-class potential as an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as

the only once-daily oral treatment option for these diseases requiring life-long treatment.

NXP900 is an oral small molecule inhibitor

of the SRC Family of Kinases (SFK), including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase,

providing comprehensive shutdown of the signaling pathway.

NXP200 is an oral, brain penetrant,

paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including

CNS, colorectal cancer CRC, melanoma, and NSCLC, with best-in-class potential.

Forward Looking Statements

This press release contains “forward-looking

statements” within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All

statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking

statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”,

“contemplate”, “could”, “estimate”, “expect”, “intend”, “seek”,

“may”, “might”, “plan”, “potential”, “predict”, “project”, “target”,

“aim”, “should”, “will”, “would”, or the negative of these words or other similar expressions,

although not all forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.’s

current expectations and interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics,

pharmacodynamics, and efficacy data generated to date for its pipeline products NXP100, NXP200, and NXP900, and estimates and projections

regarding our financial condition. The outcomes of the events described in these forward-looking statements are subject to inherent uncertainties,

risks, assumptions, market and other conditions, and other factors that are difficult to predict. Further, certain forward-looking statements

are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties may also be subject

to market and other conditions and described more fully in the section titled “Risk Factors” in our first quarter 2026 Form

10-Q and our other public filings with the U.S. Securities and Exchange Commission (“SEC”). However, these risks are not

exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties

that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking

statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking

to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations

or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we

claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Other than statements of historical fact, all statements are considered forward-looking statements and are based on our interpretations

of past events as well as current expectations, estimates, and projections.

Company Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact:

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

GRAPHIC

Filename: tm2618439d1_ex99-1img001.jpg · Sequence: 6

Binary file (3233 bytes)

Download tm2618439d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 22, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 22, 2026

Entity File Number

001-41264

Entity Registrant Name

Nuvectis Pharma, Inc.

Entity Central Index Key

0001875558

Entity Tax Identification Number

86-2405608

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 Bridge Plaza Suite 275

Entity Address, City or Town

Fort Lee

Entity Address, State or Province

Entity Address, Postal Zip Code

07024

City Area Code

201

Local Phone Number

614-3150

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

NVCT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration